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ISOLATED NEUROGENIC BLADDER ASSOCIATED WITH HUMAN T-LYMPHOTROPIC 
VIRUS TYPE 1 INFECTION IN A RENAL TRANSPLANT PATIENT FROM CENTRAL 
AUSTRALIA. 
Introduction 
Human T cell Lymphotropic virus type 1(HTLV-1) is a retrovirus affecting 15–20 million people 
worldwide (1). The virus is endemic to South Western Japan(2), the Caribbean islands(3), sub-
Saharan Africa(4), parts of South America, Middle East and Oceania. HTLV-1 is predominately 
transmitted during breast-feeding, sexual intercourse and blood transfusions.Central Australia has the 
highest reported adult prevalence of HTLV-1 infection in the world; exceeding 40% in remote 
communities where surveys have been performed (5). Common disease associations of HTLV-1 
infection in Central Australia are bronchiectasis, blood stream infections, lower respiratory tract 
infections and strongyloidiasis (6). Three cases of adult T cell leukaemia/lymphoma (ATL) and 4 
cases of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) have been reported 
(7). In solid organ transplantation only 13 cases of HAM/TSP have been reported worldwide (8). A 
HTLV-1 proviral load greater than 1000 per 105 peripheral blood leukocytes is strongly associated 
with an increased risk and progression of HAM/TSP (9, 10). 
This is probably the first case report of isolated neurogenic bladder without features of HAM/TSP, 
attributable to HTLV-1 infection in an Aborigine renal allograft recipient.  
Case report 
A 50-year-old Indigenous woman from Alice Springs was treated with haemodialysis for five years, 
for chronic kidney disease secondary to diabetic nephropathy following which she received a 
cadaveric renal transplantation in 2014. There were 5 out of 6 antigens mismatches. There were no 
pre-existing Class 1 or II antibodies detected. She did not have features of autonomic dysfunction and 
did not have lower urinary tract symptoms prior to transplantation.  Immunosuppression was induced 
with basiliximab and maintained with mycophenolate mofetil, tacrolimus and prednisolone along with 
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standard CMV and Pneumocystis jiroveci pneumonia (PJP) prophylaxis. She had serological evidence 
of HTLV-1, Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) infection prior to transplantation. 
She had chronic hepatitis B with Core antibodies present, HBV DNA by PCR was not detected and 
strongyloides serology was negative. The donor was not tested for HTLV-1. She had delayed allograft 
function. A day 13 renal allograft biopsy showed acute tubular necrosis with no evidence of acute 
rejection. 
 A week after transplantation, an ultrasound examination showed post void residual urine volume of 
220 mls, with mild graft hydronephrosis. This was complicated by recurrent urinary tract infections 
(UTI) with extended spectrum beta lactamase (ESBL) producing Escherichia coli and graft 
dysfunction. Urodynamic studies were performed a month after transplantation revealing features of 
stress incontinence and detrusor overactivity, with no intrinsic urethral sphincter deficiency. These 
abnormalities persisted over the next six months. Her diabetes was adequately controlled. Four 
months after transplantation CMV DNA levels were 9390 copies/ml during, which improved with 
valgancyclovir. Pre-transplantation the HTLV-1 proviral load was 947.2 copies per 105 peripheral 
blood leucocytes. This increased to 6152.04 copies per 105 peripheral blood leucocytes 7 months after 
transplantation. There was CSF lymphocytic pleiocytosis with mainly small lymphocytes with mildly 
elevated CSF protein (0.57 g/L; normal range, 0.15-0.45g/L) and normal CSF glucose levels (3.1 
mmol/L; normal range, 2.7-4.2 mmol/L). The cerebrospinal fluid (CSF) proviral load was 46,400 
copies per 105 peripheral blood leucocytes. The MRI myelogram did not show evidence of myelitis. 
High HTLV-1 proviral loads in peripheral blood and CSF, lead to the diagnosis of HTLV-1 related 
bladder dysfunction. She was managed with continuous bladder drainage and intermittent clean 
bladder catheterisation. A renal graft biopsy performed for deterioration in renal allograft function 
showed features of acute pyelonephritis. A suprapubic catheter was inserted for continuous drainage. 
This resulted in stabilisation of graft function, but she had chronic colonisation of the bladder with 
ESBL Escherichia coli. 
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Discussion 
The lifetime risk of developing HTLV-1 associated myelopathy and tropical spastic paraparesis 
(HAM/TSP) is variable (between 0.25-4%) and is perhaps dependent on the route of infection, 
ethnicity and human leukocyte antigen (HLA) subtypes(11). The risk of subsequently developing 
adult T cell leukaemia/lymphoma (ATL) is 1-5% and appears to be dependent on the region the 
patient belongs(11).  Neurogenic bladder is known to occur in patients with HTLV-1 HAM/TSP and 
may be its first manifestation. Isolated neurogenic bladder dysfunction in HTLV-1 infected 
individuals without HAM/TSP has been reported in general population and the risk is estimated to be 
4.3% and  HTLV-1 proviral loads were found to be higher in these patients compared with 
asymptomatic carriers (12).  
This report describes a patient with isolated bladder dysfunction without features of HAM/TSP in a 
renal allograft recipient with HTLV-1 infection. The symptoms of bladder dysfunction became 
apparent after renal transplantation, probably because she had minimal urine output while she was on 
dialysis. During early and later stages of chronic kidney disease, she did not suffer from urinary tract 
infections and ultrasound demonstrated normal bladder wall with normal post void volume of less 
than 50 mls. She did not have classical features of diabetic cystopathy, as the urodynamic study did 
not show reduced detrusor contractility and areflexia. The study showed detrusor overactivity with no 
intrinsic urethral sphincter deficiency.  Detrusor overactivity has been reported as the most frequent 
urodynamic finding with HTLV-1 infection. In our patient, post void residual volume of 220 ml is 
elevated possibly due to detrusor-external sphincter dyssynergia. Both disorders could possibly 
coexist as part of the neurogenic bladder (20). 
Majority of the renal transplant recipients who developed HAM/TSP were HTLV-1 seronegative prior 
to transplantation and acquired the infection from the donor (8). The donor was not tested for HTLV-
1 infection, but was residing in a region of low endemicity. The development of HAM/TSP in an 
HTLV-1 seropositive graft recipient is uncommon. In this case, the HTLV-1 proviral load in the 
blood and CSF exceeded 1000 per 10^5 PBL associated with CSF lymphocytic pleiocytosis, 
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consistent with HTLV-1 associated neurological disease. The high proviral load in the pathogenesis of 
HTLV-1–associated disease is supported by the observation that when the proviral load exceeds a 
threshold level HTLV-I-specific cytotoxic T lymphocytes could contribute to inflammation and 
damage to the nervous system (21). 
The effect of immunosuppression on the natural history of HTLV-1 infection is unknown. 
Paradoxically, cyclosporine and prednisolone have been used to treat patients with HAM/TSP (13), 
yet the acquisition of HTLV-1 infection in the setting of solid organ transplantation appears to be 
associated with an increased risk of developing HAM/TSP. Nevertheless, overall graft survival does 
not differ between HTLV-1 positive and negative recipients (14-17). Most people living with HTLV-I 
infection are asymptomatic and neurological disease may develop in some patients after solid organ 
transplantation who are serologically either HTLV-1 donor positive/recipient negative or donor 
negative/recipient negative.  According to Clinical Guidelines for Organ Transplantation from 
Deceased Donors published by Transplantation Society of Australia and New Zealand (April 2016), 
epidemiologic exposure to HTLV-I must be determined during pre-transplantation evaluation and 
selective screening of donors and recipients with HTLV-I risk factors should be considered in regions 
of high endemicity. Routine screening of donors for HTLV-infection in populations with low 
prevalence is not recommended (14, 18). HTLV-I positive potential solid organ transplant recipients 
should be informed about the higher risk of  diseases such as ATL, with development rates of 20% 
over 5 years (19) and HAM/TSP as part of the informed consent process, as there is no available 
treatment for this infection.  Detection of HTLV-I infection early in the post-transplant course should 
also include monitoring of infected recipients for evidence of clinical disease, and timely 
implementation of various management strategies.  
Conclusion 
Isolated bladder dysfunction is a rare manifestation of HTLV-1 infection associated with high proviral 
load, which may adversely affect graft and patient outcomes following kidney transplantation. 
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Highlights 
 
• First case report of isolated neurogenic bladder without features myelopathy/tropical spastic 
paraparesis, attributable to HTLV-1 infection in an Aborigine renal allograft recipient. 
• Isolated bladder dysfunction is a rare manifestation of HTLV-1 infection associated with high 
proviral load 
• Adversely affect graft and patient outcomes following kidney transplantation. 
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ISOLATED NEUROGENIC BLADDER ASSOCIATED WITH HUMAN T-LYMPHOTROPIC 
VIRUS TYPE 1 INFECTION IN A RENAL TRANSPLANT PATIENT FROM CENTRAL 
AUSTRALIA. 
 
Abstract 
Background: Human T-Lymphotropic virus type 1 (HTLV-1) is endemic amongst the Aborigines of 
the Northern Territory of Australia. HTLV-1 associated Myelopathy/Tropical Spastic paraparesis 
(HAM/TSP) has been associated with this infection. In general population, isolated neurogenic 
bladder dysfunction in HTLV-1–infected individuals without HAM/TSP has been reported and the 
HTLV-1 proviral load has been found to be higher in such patients compared with asymptomatic 
carriers. In solid organ transplantation, few cases of HAM/TSP have been reported worldwide but not 
an isolated neurogenic bladder.  
Case: A 50-year-old indigenous women from Alice Springs with end stage renal disease secondary to 
diabetic nephropathy with no prior history of bladder dysfunction received a cadaveric renal allograft 
following which she developed recurrent urinary tract infections. The recipient was seropositive for 
HTLV-1 infection. HTLV-1 status of donor was not checked. Urodynamic studies revealed stress 
incontinence and detrusor overactivity without urethral intrinsic sphincter deficiency. She had no 
features of myelopathy. There was elevation of the serum and cerebrospinal fluid (CSF) HTLV-1 
proviral load. The MRI myelogram was normal. Pyelonephritis was diagnosed based on clinical 
features, positive cultures and renal allograft biopsy. Continuous suprapubic catheter drainage helped 
preventing further episodes of allograft pyelonephritis in spite of chronic colonisation of the urinary 
tract. 
Conclusion: Isolated bladder dysfunction is a rare manifestation of HTLV-1 infection and is probably 
associated with high proviral loads. This may adversely affect renal allograft and patient outcomes. 
 
